Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion

Incyte, Galmed Pharmaceuticals, and Johnson & Johnson announced three separate corporate acquisitions this week, marking a continued trend of dealmaking across the pharmaceutical and medical technology sectors. The transactions include Incyte’s purchase of Vega Therapeutics, Galmed Pharmaceuticals’ acquisition of Colospan, and Johnson & Johnson’s takeover of Firefly Bio.

Incyte secured Vega Therapeutics in a deal valued at $2 billion, gaining control of a Phase III antibody candidate designed to treat bleeding disorders. Simultaneously, Galmed Pharmaceuticals shifted its strategic focus toward the gastrointestinal medical technology market through its acquisition of Colospan. Rounding out the week’s activity, Johnson & Johnson finalized a $1 billion agreement to acquire Firefly Bio, a move that expands the company’s portfolio into the development of KRAS-targeting degrader conjugates.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 8, 2026

Author

GOAI